Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

In vitro and in vivo evaluation of a non-carbohydrate targeting platform for lysosomal proteins.

Stefano JE, Hou L, Honey D, Kyazike J, Park A, Zhou Q, Pan CQ, Edmunds T.

J Control Release. 2009 Apr 17;135(2):113-8. doi: 10.1016/j.jconrel.2008.12.006. Epub 2008 Dec 24.

PMID:
19146893
2.

Lysosomal storage diseases and the blood-brain barrier.

Begley DJ, Pontikis CC, Scarpa M.

Curr Pharm Des. 2008;14(16):1566-80. Review.

PMID:
18673198
3.

[Lysosomes and lysosomal storage diseases].

Germain DP.

J Soc Biol. 2002;196(2):127-34. Review. French.

PMID:
12360741
4.

Insulin-like growth factor-2/mannose-6 phosphate receptors.

El-Shewy HM, Luttrell LM.

Vitam Horm. 2009;80:667-97. doi: 10.1016/S0083-6729(08)00624-9. Review.

PMID:
19251055
5.
6.

Glycosylation- and phosphorylation-dependent intracellular transport of lysosomal hydrolases.

Pohl S, Marschner K, Storch S, Braulke T.

Biol Chem. 2009 Jul;390(7):521-7. doi: 10.1515/BC.2009.076. Review.

PMID:
19426136
7.

Strategies to improve plasma half life time of peptide and protein drugs.

Werle M, Bernkop-Schnürch A.

Amino Acids. 2006 Jun;30(4):351-67. Epub 2006 Apr 20. Review.

PMID:
16622600
8.

Molecular pathologies of and enzyme replacement therapies for lysosomal diseases.

Sakuraba H, Sawada M, Matsuzawa F, Aikawa S, Chiba Y, Jigami Y, Itoh K.

CNS Neurol Disord Drug Targets. 2006 Aug;5(4):401-13. Review.

PMID:
16918392
9.

Protein-specific glycosylation: signal patches and cis-controlling peptidic elements.

Hanisch FG, Breloy I.

Biol Chem. 2009 Jul;390(7):619-26. doi: 10.1515/BC.2009.043. Review.

PMID:
19284292
10.

[Division-related function and organ-related therapy in Fabry's disease. An interdisciplinary challenge].

Weidemann F, Sommer C, Duning T, Lanzl I, Möhrenschlager M, Naleschinski D, Baron R, Breunig F, Schaefer R, Strotmann J, Wanner C.

Med Klin (Munich). 2009 Jan 15;104(1):10-9. doi: 10.1007/s00063-009-1003-0. Epub 2009 Jan 14. Review. German.

PMID:
19142592
11.

Strategies for extended serum half-life of protein therapeutics.

Kontermann RE.

Curr Opin Biotechnol. 2011 Dec;22(6):868-76. doi: 10.1016/j.copbio.2011.06.012. Epub 2011 Aug 20. Review.

PMID:
21862310
12.

Lysosomal modulatory drugs for a broad strategy against protein accumulation disorders.

Bahr BA.

Curr Alzheimer Res. 2009 Oct;6(5):438-45. Review.

PMID:
19874268
13.

Appropriating microbial catabolism: a proposal to treat and prevent neurodegeneration.

de Grey AD.

Neurobiol Aging. 2006 Apr;27(4):589-95. Epub 2005 Oct 3. Review.

PMID:
16207503
14.

The cation-dependent mannose 6-phosphate receptor.

Kim JJ, Dahms NM.

Results Probl Cell Differ. 2001;33:39-56. Review. No abstract available.

PMID:
11190678
15.

PEGylation--a well-proven strategy for the improvement of recombinant drugs.

Zündorf I, Dingermann T.

Pharmazie. 2014 May;69(5):323-6. Review.

PMID:
24855821
16.

Recent advances in the biochemistry and genetics of sphingolipidoses.

Ozkara HA.

Brain Dev. 2004 Dec;26(8):497-505. Review.

PMID:
15533650
17.

Targeting of proteins to the lysosome.

Pfeffer SR.

Curr Top Microbiol Immunol. 1991;170:43-65. Review. No abstract available.

PMID:
1662126
18.

Enzyme replacement therapy – a brief history.

Neufeld EF.

In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 10.

19.

Modification of clearance of therapeutic and potentially therapeutic proteins.

Sheffield WP.

Curr Drug Targets Cardiovasc Haematol Disord. 2001 Jun;1(1):1-22. Review.

PMID:
12769661
20.

[Problems and solutions in pegylation of protein and peptide drugs].

Jiang ZY, Gao R, Wang YQ, Sun Y.

Yao Xue Xue Bao. 2002 May;37(5):396-400. Review. Chinese. No abstract available.

PMID:
12579849

Supplemental Content

Support Center